AstraZeneca och Bristol-Meyers Squibb meddelar att amerikanska FDA har godkänt Farxiga™ (dapagliflozin)

AstraZeneca och Bristol-Myers Squibb meddelar idag att amerikanska FDA (US Food and Drug Administration) godkänner Farxiga ™ (dapagliflozin).

Företagen kommer att ge ytterligare detaljer om godkännande i ett kommande pressmeddelande.

.

– ENDS –

NOTES TO EDITORS

About the AstraZeneca/Bristol-Myers Squibb Diabetes Alliance

Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find out more about the Alliance and our commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com or www.bms.com.  

On December 19, 2013 AstraZeneca and Bristol-Myers Squibb announced an agreement under which AstraZeneca will acquire the entirety of Bristol-Myers Squibb’s interests in the companies’ diabetes alliance to consolidate worldwide ownership of the diabetes business within AstraZeneca. The closing of the transactions contemplated by the agreement is subject to customary terms and conditions, and is expected to occur during the first quarter of 2014.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

For more information about Bristol-Myers Squibb, visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

CONTACTS

Media Enquiries

Esra Erkal-Paler                          +44 20 7604 8030 (UK/Global)

Vanessa Rhodes                         +44 20 7604 8037 (UK/Global)

Ayesha Bharmal                          +44 20 7604 8034 (UK/Global)

Tracy Rossin                                              +1 301 398 1468 (US)

Jacob Lund                                 +46 8 553 260 20 (Sweden)

Investor Enquiries

Karl Hård                                    +44 20 7604 8123  mob: +44 7789 654364

Colleen Proctor                           + 1 302 886 1842     mob: +1 302 357 4882

Anthony Brown                           +44 20 7604 8067   mob: +44 7585 404943

Jens Lindberg                             +44 20 7604 8414   mob: +44 7557 319729

Taggar: